{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:02:40Z","timestamp":1789470160884,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.medj.2024.11.016","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T10:39:07Z","timestamp":1736505547000},"page":"100563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Belzutifan for renal cell carcinoma: Balancing regulatory approval with societal and patient impact"],"prefix":"10.1016","volume":"6","author":[{"given":"Jad","family":"Chahoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.11.016_bib1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.11.016_bib2","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-24-1199","article-title":"FDA Approval Summary: Belzutifan for Patients with Advanced Renal\u00a0Cell Carcinoma","volume":"30","author":"Fallah","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.11.016_bib3","article-title":"Decoding Randomized Controlled Trials: An Information Science Perspective","volume":"6","author":"Msaouel","year":"2024","journal-title":"Harv. Data Sci. Rev."},{"key":"10.1016\/j.medj.2024.11.016_bib4","article-title":"Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses","volume":"8","author":"Sherry","year":"2024","journal-title":"JCO Clin. Cancer Inform."},{"key":"10.1016\/j.medj.2024.11.016_bib5","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/jnci\/djaa174","article-title":"Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review","volume":"113","author":"Safa","year":"2021","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.medj.2024.11.016_bib6","first-page":"00701","article-title":"Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think\u00a0tank meeting","volume":"S1078\u20131439","author":"Berg","year":"2024","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.medj.2024.11.016_bib7","unstructured":"FDA. Multiple Endpoints in Clinical Trials: Guidance for Industry.(2022). Docket No. FDA 2016-D-4460. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/multiple-endpoints-clinical-trials."},{"key":"10.1016\/j.medj.2024.11.016_bib8","series-title":"Belzutifan (Welireg)","year":"2023"},{"key":"10.1016\/j.medj.2024.11.016_bib9","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received","volume":"34","author":"Schnipper","year":"2016","journal-title":"J.\u00a0Clin. Oncol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024004574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024004574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:01:54Z","timestamp":1768014114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024004574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2666634024004574"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.11.016","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Belzutifan for renal cell carcinoma: Balancing regulatory approval with societal and patient impact","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100563"}}